AUTL: Prakiraan pendapatan perusahaan Autolus Therapeutics PLC

The Autolus Therapeutics (AUTL) personalized medicine manufacturing plant is operating at full capacity, implementing automation to scale volumes. The valuation of the organization's prospective sales confirms asset resilience, with the 0.14 mark indicating the level of current expectations. Structural flexibility is maintained through the outsourcing of clinical trials and vector production. Growth is driven by the market launch of Aucatzyl and the partnership with BioNTech.

Autolus Corp - Pendapatan mangsa ngarep perusahaan AUTL (periode 04.07.2022 - 15.11.2026)

Ringkesan rincian data analitis Autolus Corp (AUTL)

- nilai saham lan prakiraan konsensus rega:

Bagan rega Autolus Therapeutics plc|AUTL - Bagan rega target

- informasi kapitalisasi pasar:

Nilai pasar Autolus Corp|AUTL - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Nilai Akuntansi saben Saham Autolus Therapeutics|AUTL - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku autolus.com|AUTL - Aset Neraca Perusahaan

- statistik kawajiban utang lan likuiditas:

Total Utang marang Modal Autolus Therapeutics|AUTL - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Autolus Therapeutics plc|AUTL - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Autolus Therapeutics PLC|AUTL - Utang jangka dawa|Kewajiban jangka cendhak perusahaan Autolus Therapeutics|Indikator likuiditas cepet autolus.com

- rincian asil keuangan lan kelipatan valuasi:

AUTL - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Autolus Therapeutics|AUTL - Nilai perusahaan marang bathi resik|Pangali Forward P/E autolus.com|AUTL - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Autolus Therapeutics|AUTL - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Autolus Therapeutics|AUTL - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan autolus.com|AUTL - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Autolus Therapeutics

- informasi babagan volume dodolan lan pendapatan:

AUTL - Total pendapatan perusahaan|Prakiraan volume dodolan autolus.com|AUTL - Multiplikator P/S|Multiplikator forward rega marang pendapatan Autolus Pharma|AUTL - Wutah dodolan YoY (TTM)

Ringkesan analitik perusahaan:Autolus Corp

This indicator represents the discounted value of projected cash flows from sales, adjusted for the cost of capital to determine the current fundamental value of the business. An analysis of Autolus Therapeutics (AUTL) estimated sales volume allows for an assessment of the monetization of its unique cell programming platform, considering the high switching costs for hospitals to move to alternative therapy methods within the established ecosystem.

Pesaing Autolus Therapeutics (AUTL)

Prakiraan pendapatan perusahaan Legend Biotech Corporation (LEGN)|Prakiraan pendapatan perusahaan SANA (Sana Biotechnology Inc)|Prakiraan pendapatan perusahaan Allogene Therapeutics Inc ALLO|Cartesian Therapeutics - Prakiraan pendapatan perusahaan|CLLS: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan CRBU (Caribou Biosciences)|TIL: Prakiraan volume dodolan|Prakiraan dodolan perusahaan Genenta Science SpA GNTA|IPSC (Century Tx) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan jaspertherapeutics.com JSPR|Prakiraan pendapatan perusahaan Senti Biosciences Inc (SNTI)|Adaptimmune Therapeutics - Prakiraan pendapatan perusahaan|Prakiraan volume dodolan CERO (CERo Therapeutics Holdings)|alaunos.com (TCRT) - Volume dodolan sing dikarepake perusahaan|ACHL: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan CRGX (CARGO Therapeutics)|PSTX (Poseida) - Volume dodolan mangsa ngarep perusahaan|TSVT: Prakiraan volume pendapatan perusahaan|GRCL (Gracell Biotechnologies Inc.) - Prakiraan volume dodolan